Fundamental and clinical evaluation of a new orally administrable cephalosporin, cefaclor in pediatric field

Hironobu Akita, Masahiro Hotta, Naoya Yamashita, Seiichiro Nanri, Keisuke Sunakawa, Noriyoshi Hara, Yoshibumi Kojima, Mitsuru Osano, Yasuo Ichihashi, Takeo Kori, Satoshi Iwata, Mari Sakamoto, Yoshitake Sato

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Cefaclor, a new orally administrable cephalosporin, was evaluated fundamentally and clinically in children and following results were obtained. (1) Serum levels of orally administered cefaclor were measured and, revealed a prompt rise and fall with a half life of 20∼50 minutes. Maximal serum level was obtained 30 minutes after administration and was 16.5 μg/ml by a single oral dose of 25 mg/kg of body weight. Following serum concentrations of cefaclor were one hour, 11.2 μg/ml, 2 hours, 2.27μg/ml, 4 hours, 0.77 μg/ml and 6 hours, 0.2 μg/ml respectively. (2) Maximal serum concentration was lower than that of cephalexin (CEX). This might be the result of relative unstability of cefaclor compared with CEX. (3) Clinical evaluation was done in 31 cases, consisting of 18 cases in upper respiratory infection, 8 cases in bronchitis and bronchopneumonia, 3 cases in urinary tract infection and 2 other cases. The results of 29 out of 31 cases were excellent and good clinically. (4) Among 16 cases, in which pathological microorganisms were isolated from their throat or urine, 14 cases (88%) revealed good responses bacteriologically. (5) According to these results, it was suggested that cefaclor is more effective on respiratory and urinary tract infections with lesser side effects than CEX is, and useful in pediatric field.

Original languageEnglish
Pages (from-to)355-361
Number of pages7
JournalChemotherapy
Volume27
DOIs
Publication statusPublished - 1979
Externally publishedYes

Fingerprint

Cefaclor
Cephalosporins
Cephalexin
Pediatrics
Serum
Urinary Tract Infections
Respiratory Tract Infections
Bronchopneumonia
Bronchitis
Pharynx
Half-Life
Body Weight
Urine

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Drug Discovery
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Fundamental and clinical evaluation of a new orally administrable cephalosporin, cefaclor in pediatric field. / Akita, Hironobu; Hotta, Masahiro; Yamashita, Naoya; Nanri, Seiichiro; Sunakawa, Keisuke; Hara, Noriyoshi; Kojima, Yoshibumi; Osano, Mitsuru; Ichihashi, Yasuo; Kori, Takeo; Iwata, Satoshi; Sakamoto, Mari; Sato, Yoshitake.

In: Chemotherapy, Vol. 27, 1979, p. 355-361.

Research output: Contribution to journalArticle

Akita, H, Hotta, M, Yamashita, N, Nanri, S, Sunakawa, K, Hara, N, Kojima, Y, Osano, M, Ichihashi, Y, Kori, T, Iwata, S, Sakamoto, M & Sato, Y 1979, 'Fundamental and clinical evaluation of a new orally administrable cephalosporin, cefaclor in pediatric field', Chemotherapy, vol. 27, pp. 355-361. https://doi.org/10.11250/chemotherapy1953.27.Supplement7_355
Akita, Hironobu ; Hotta, Masahiro ; Yamashita, Naoya ; Nanri, Seiichiro ; Sunakawa, Keisuke ; Hara, Noriyoshi ; Kojima, Yoshibumi ; Osano, Mitsuru ; Ichihashi, Yasuo ; Kori, Takeo ; Iwata, Satoshi ; Sakamoto, Mari ; Sato, Yoshitake. / Fundamental and clinical evaluation of a new orally administrable cephalosporin, cefaclor in pediatric field. In: Chemotherapy. 1979 ; Vol. 27. pp. 355-361.
@article{34abb7c39b5743bfaf5f08c3f065f2f1,
title = "Fundamental and clinical evaluation of a new orally administrable cephalosporin, cefaclor in pediatric field",
abstract = "Cefaclor, a new orally administrable cephalosporin, was evaluated fundamentally and clinically in children and following results were obtained. (1) Serum levels of orally administered cefaclor were measured and, revealed a prompt rise and fall with a half life of 20∼50 minutes. Maximal serum level was obtained 30 minutes after administration and was 16.5 μg/ml by a single oral dose of 25 mg/kg of body weight. Following serum concentrations of cefaclor were one hour, 11.2 μg/ml, 2 hours, 2.27μg/ml, 4 hours, 0.77 μg/ml and 6 hours, 0.2 μg/ml respectively. (2) Maximal serum concentration was lower than that of cephalexin (CEX). This might be the result of relative unstability of cefaclor compared with CEX. (3) Clinical evaluation was done in 31 cases, consisting of 18 cases in upper respiratory infection, 8 cases in bronchitis and bronchopneumonia, 3 cases in urinary tract infection and 2 other cases. The results of 29 out of 31 cases were excellent and good clinically. (4) Among 16 cases, in which pathological microorganisms were isolated from their throat or urine, 14 cases (88{\%}) revealed good responses bacteriologically. (5) According to these results, it was suggested that cefaclor is more effective on respiratory and urinary tract infections with lesser side effects than CEX is, and useful in pediatric field.",
author = "Hironobu Akita and Masahiro Hotta and Naoya Yamashita and Seiichiro Nanri and Keisuke Sunakawa and Noriyoshi Hara and Yoshibumi Kojima and Mitsuru Osano and Yasuo Ichihashi and Takeo Kori and Satoshi Iwata and Mari Sakamoto and Yoshitake Sato",
year = "1979",
doi = "10.11250/chemotherapy1953.27.Supplement7_355",
language = "English",
volume = "27",
pages = "355--361",
journal = "Chemotherapy",
issn = "0009-3165",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Fundamental and clinical evaluation of a new orally administrable cephalosporin, cefaclor in pediatric field

AU - Akita, Hironobu

AU - Hotta, Masahiro

AU - Yamashita, Naoya

AU - Nanri, Seiichiro

AU - Sunakawa, Keisuke

AU - Hara, Noriyoshi

AU - Kojima, Yoshibumi

AU - Osano, Mitsuru

AU - Ichihashi, Yasuo

AU - Kori, Takeo

AU - Iwata, Satoshi

AU - Sakamoto, Mari

AU - Sato, Yoshitake

PY - 1979

Y1 - 1979

N2 - Cefaclor, a new orally administrable cephalosporin, was evaluated fundamentally and clinically in children and following results were obtained. (1) Serum levels of orally administered cefaclor were measured and, revealed a prompt rise and fall with a half life of 20∼50 minutes. Maximal serum level was obtained 30 minutes after administration and was 16.5 μg/ml by a single oral dose of 25 mg/kg of body weight. Following serum concentrations of cefaclor were one hour, 11.2 μg/ml, 2 hours, 2.27μg/ml, 4 hours, 0.77 μg/ml and 6 hours, 0.2 μg/ml respectively. (2) Maximal serum concentration was lower than that of cephalexin (CEX). This might be the result of relative unstability of cefaclor compared with CEX. (3) Clinical evaluation was done in 31 cases, consisting of 18 cases in upper respiratory infection, 8 cases in bronchitis and bronchopneumonia, 3 cases in urinary tract infection and 2 other cases. The results of 29 out of 31 cases were excellent and good clinically. (4) Among 16 cases, in which pathological microorganisms were isolated from their throat or urine, 14 cases (88%) revealed good responses bacteriologically. (5) According to these results, it was suggested that cefaclor is more effective on respiratory and urinary tract infections with lesser side effects than CEX is, and useful in pediatric field.

AB - Cefaclor, a new orally administrable cephalosporin, was evaluated fundamentally and clinically in children and following results were obtained. (1) Serum levels of orally administered cefaclor were measured and, revealed a prompt rise and fall with a half life of 20∼50 minutes. Maximal serum level was obtained 30 minutes after administration and was 16.5 μg/ml by a single oral dose of 25 mg/kg of body weight. Following serum concentrations of cefaclor were one hour, 11.2 μg/ml, 2 hours, 2.27μg/ml, 4 hours, 0.77 μg/ml and 6 hours, 0.2 μg/ml respectively. (2) Maximal serum concentration was lower than that of cephalexin (CEX). This might be the result of relative unstability of cefaclor compared with CEX. (3) Clinical evaluation was done in 31 cases, consisting of 18 cases in upper respiratory infection, 8 cases in bronchitis and bronchopneumonia, 3 cases in urinary tract infection and 2 other cases. The results of 29 out of 31 cases were excellent and good clinically. (4) Among 16 cases, in which pathological microorganisms were isolated from their throat or urine, 14 cases (88%) revealed good responses bacteriologically. (5) According to these results, it was suggested that cefaclor is more effective on respiratory and urinary tract infections with lesser side effects than CEX is, and useful in pediatric field.

UR - http://www.scopus.com/inward/record.url?scp=0018574361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018574361&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.27.Supplement7_355

DO - 10.11250/chemotherapy1953.27.Supplement7_355

M3 - Article

AN - SCOPUS:0018574361

VL - 27

SP - 355

EP - 361

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3165

ER -